Caprini Vte Score Calculator
Assess venous thromboembolism risk in surgical patients using the Caprini scoring system. Enter values for instant results with step-by-step formulas.
Formula
Caprini Score = Sum of weighted risk factors (1, 2, 3, or 5 points each)
The Caprini score assigns weighted points to approximately 40 risk factors: 1 point for minor factors (age 41-60, BMI > 25, varicose veins), 2 points for moderate factors (age 61-74, major surgery > 45 min, malignancy), 3 points for significant factors (age >= 75, prior VTE, thrombophilia), and 5 points for major factors (stroke, arthroplasty, spinal cord injury). Total score determines VTE risk category and prophylaxis intensity.
Worked Examples
Example 1: Moderate Risk General Surgery Patient
Problem: A 55-year-old woman (BMI 28) is scheduled for elective laparoscopic cholecystectomy expected to last 60 minutes. She has varicose veins and takes oral contraceptives. No history of VTE.
Solution: Caprini Score:\nAge 41-60: 1 point\nBMI > 25: 1 point\nVaricose veins: 1 point\nOral contraceptives: 1 point\nLaparoscopic surgery > 45 min: 2 points\nTotal = 6 points\nRisk Category: High Risk\nVTE incidence: 6.5 - 11.3%
Result: Score 6 (High Risk) | VTE risk 6.5-11.3% | LMWH + IPC recommended
Example 2: High Risk Orthopedic Surgery Patient
Problem: A 76-year-old man is undergoing total hip arthroplasty. He has a history of DVT 3 years ago and is heterozygous for Factor V Leiden mutation. He also has a history of CHF.
Solution: Caprini Score:\nAge >= 75: 3 points\nElective hip arthroplasty: 5 points\nPrior DVT: 3 points\nFactor V Leiden: 3 points\nCHF (< 1 month): 1 point\nTotal = 15 points\nRisk Category: High Risk\nVTE incidence: >11.3% without prophylaxis
Result: Score 15 (High Risk) | LMWH/DOAC + IPC + 35 days extended prophylaxis
Frequently Asked Questions
What is the Caprini score and what does it assess?
The Caprini score is a validated risk assessment model (RAM) developed by Dr. Joseph Caprini that estimates a surgical patient's risk of developing venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). The score assigns weighted points to approximately 40 individual risk factors organized into four tiers: 1-point factors, 2-point factors, 3-point factors, and 5-point factors. These risk factors encompass patient demographics (age), surgical factors (type and duration), medical comorbidities, mobility status, thrombophilia states, and prior VTE history. The cumulative score stratifies patients into lowest, low, moderate, and high VTE risk categories, guiding decisions about the type and duration of thromboprophylaxis. The Caprini model has been validated in over 250,000 surgical patients.
How is the Caprini score used to guide VTE prophylaxis decisions?
The Caprini score translates directly into specific prophylaxis recommendations based on the risk tier. Patients with a score of 0 (lowest risk, VTE incidence less than 0.5 percent) require only early ambulation. Scores of 1 to 2 (low risk, VTE incidence 0.7 to 1.8 percent) warrant mechanical prophylaxis with intermittent pneumatic compression (IPC) devices or graduated compression stockings. Scores of 3 to 4 (moderate risk, VTE incidence 2.0 to 6.3 percent) indicate pharmacological prophylaxis with low-molecular-weight heparin (LMWH), low-dose unfractionated heparin (UFH), or fondaparinux, combined with mechanical prophylaxis. Scores of 5 or higher (high risk, VTE incidence 6.5 to 11.3 percent) require aggressive pharmacological prophylaxis combined with mechanical measures, and extended-duration prophylaxis (up to 30 days) should be considered, particularly for cancer surgery and major orthopedic procedures.
What pharmacological agents are used for VTE prophylaxis in surgical patients?
Several pharmacological agents are approved and recommended for VTE prophylaxis in surgical patients. Low-molecular-weight heparins (LMWH) such as enoxaparin (40 mg subcutaneously once daily) and dalteparin (5000 IU subcutaneously once daily) are the most commonly used agents due to their predictable pharmacokinetics, once-daily dosing, and favorable safety profile. Low-dose unfractionated heparin (UFH) at 5000 units subcutaneously every 8 to 12 hours is an alternative, particularly in patients with renal insufficiency. Fondaparinux (2.5 mg subcutaneously once daily) is a synthetic Factor Xa inhibitor used when heparin-induced thrombocytopenia is a concern. Direct oral anticoagulants (DOACs) including rivaroxaban, apixaban, and dabigatran are increasingly used for extended prophylaxis after major orthopedic surgery. Aspirin alone may be considered for lower-risk joint arthroplasty patients according to some guideline updates.
What is the evidence base for extended VTE prophylaxis after surgery?
Extended VTE prophylaxis beyond the hospital stay is supported by strong evidence for specific high-risk surgical populations. The ENOXACAN II trial demonstrated that 28 days of enoxaparin after cancer surgery reduced VTE by 60 percent compared to standard 6 to 10 day prophylaxis. Multiple randomized trials (RECORD 1-4 for rivaroxaban, ADVANCE 1-3 for apixaban, RE-MODEL and RE-NOVATE for dabigatran) showed that 28 to 35 days of prophylaxis after total hip and knee arthroplasty significantly reduced symptomatic VTE and asymptomatic DVT compared to shorter courses. The Ninth ACCP Guidelines recommend extended prophylaxis for 28 to 35 days after hip arthroplasty, hip fracture surgery, and major cancer surgery. For general and abdominal-pelvic surgery with Caprini scores of 5 or higher, extended prophylaxis is recommended when bleeding risk is acceptable.
How does cancer increase VTE risk and affect Caprini score interpretation?
Cancer significantly increases VTE risk through multiple prothrombotic mechanisms, and malignancy (present or previous) receives 2 points in the Caprini score. Cancer promotes thrombosis through direct activation of the coagulation cascade by tumor-produced tissue factor and cancer procoagulant, through tumor compression of blood vessels causing venous stasis, through chemotherapy-induced endothelial damage and vascular injury, through central venous catheters used for treatment, and through cancer-related immobility and deconditioning. The risk varies by cancer type: pancreatic, brain, gastric, and ovarian cancers carry the highest VTE rates (10 to 20 percent annually). Cancer patients undergoing surgery have 2 to 3 times higher VTE rates than non-cancer patients having the same procedure. Extended prophylaxis for 4 weeks postoperatively is strongly recommended for cancer patients undergoing major abdominal or pelvic surgery.
What are the contraindications to pharmacological VTE prophylaxis?
Pharmacological VTE prophylaxis is contraindicated in several clinical scenarios where the bleeding risk outweighs the thrombotic benefit. Absolute contraindications include active major bleeding, severe uncontrolled hypertension (systolic greater than 180 mmHg), thrombocytopenia (platelets less than 50,000), known heparin-induced thrombocytopenia (for heparin products), intracranial hemorrhage within 24 hours, and spinal or epidural hematoma risk in patients with neuraxial anesthesia. Relative contraindications include coagulopathy (INR greater than 1.5), hepatic failure with coagulopathy, concurrent use of antiplatelet agents, recent surgery with high bleeding risk (such as neurosurgery within 24 hours), and severe renal insufficiency (for LMWH and fondaparinux). When pharmacological prophylaxis is contraindicated, mechanical prophylaxis with intermittent pneumatic compression devices becomes the primary prevention strategy.